Total Revenue

+1.5% " "

Modest overall growth was driven by strong performance in key segments such as Medical Devices and Established Pharmaceuticals, which helped offset a slight decline in Diagnostic Products; this trend builds on previous periods where robust segmental gains balanced out softer areas. " "

Medical Devices

+13% " "

Exceptional growth in Medical Devices continued in Q2 2025 with revenue rising from $4,734 million to $5,369 million, reflecting sustained momentum from previous periods driven by strong demand in areas like Diabetes Care and Structural Heart and benefiting from ongoing product innovations and favorable market dynamics. " "

Established Pharmaceuticals

+7% " "

Consistent expansion in the Established Pharmaceutical segment is attributable to increased sales in key emerging markets and diverse therapeutic areas, echoing earlier Q1 trends where strong organic growth was noted; this solid performance pushed revenues from $1,294 million to $1,383 million. " "

Nutritional Products

+3% " "

Modest growth in Nutritional Products—from $2,150 million to $2,212 million—reflects continued gains in U.S. Pediatric Nutritionals that are partly offset by challenges such as the discontinuation of certain product lines and international market headwinds, consistent with earlier period trends. " "

Diagnostic Products

-1% " "

A slight decline in Diagnostic Products reflects ongoing pressure from reduced COVID-19 testing demand and foreign exchange challenges; this mirrors previous period patterns where the loss in testing revenue could not be fully mitigated by gains in routine diagnostic testing portfolios. " "

United States Revenue

+9% " "

Robust U.S. performance, with revenue increasing from $3,934 million to $4,276 million, was fueled by strong growth in Medical Devices and Nutrition—especially in product categories like FreeStyle Libre—continuing the positive trends observed in previous quarters. " "

International Revenue

+7% " "

Moderate international growth (from $6,443 million to $6,866 million) was driven by solid performance in Medical Devices and Established Pharmaceuticals, although partly tempered by foreign exchange headwinds and declines in Diagnostics linked to reduced COVID-19 testing, which is in line with earlier period trends. " "

Sales Growth

FY 2025

High single-digit sales growth with a specific increase of 6.9% or 8.3% when excluding COVID testing-related sales " " " "

High single-digit sales growth for FY 2025 " "

no change

Foreign Exchange Impact

FY 2025

Expected unfavorable impact of around 1% on reported sales " " " "

Neutral impact on FY 2025 reported sales "

raised

Adjusted EPS

Q3 2025

no prior guidance

Forecast range of $1.28 to $1.32 " "

no prior guidance

Foreign Exchange Impact

Q3 2025

no prior guidance

Favorable impact of approximately 2% on Q3 2025 reported sales "

no prior guidance